Advertisement

Topics

Iroko Pharmaceuticals, LLC Company Profile

12:55 EDT 30th April 2016 | BioPortfolio

Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops and maximizes the potential of currently marketed products on a global basis through focused selling and marketing efforts and product-life-cycle management activities including development of new formulations to improve patient treatment.


News Articles [640 Associated News Articles listed on BioPortfolio]

Iroko's osteoarthritis pain drug wins FDA approval

Iroko Pharmaceuticals' Vivlodex, a low-dose, rapid-dissolution meloxicam, has received clearance from the FDA.  -More- 

Iroko Pharmaceuticals Receives FDA Approval For VIVLODEX - First Low Dose SoluMatrix Meloxicam For Osteoarthritis Pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced recently that the United States Food and Drug Administration (FDA) appr...

Survey: Patients with pain cannot identify NSAIDs, do not discuss pain with their physicians

Although an Iroko Pharmaceuticals-funded survey of 1,056 American adults showed 77% of those surveyed experienced at least some type of pain and 43% experienced pain weekly, half of respondents were u...

FDA Approves Vivlodex (meloxicam) for Osteoarthritis Pain

PHILADELPHIA, October 23, 2015 — Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that the United States Food an...

Vivlodex now available in United States for osteoarthritis pain

Iroko Pharmaceuticals LLC announced its proprietary, low-dose form of meloxicam, Vivlodex, is now available in pharmacies in the United States, according to a company press release. In a 12-week study...

Iroko announces Vivlodex availability

The low-dose NSAID was approved by the Food and Drug Administration in October to treat osteoarthritis pain.  read more

Iroko Pharmaceuticals to Present Phase 3 VIVLODEX® Efficacy and Safety Data at World Congress of Osteoarthritis

PHILADELPHIA, March 31, 2016 /PRNewswire/ -- Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that it will pr...

FDA approves Iroko's low-dose NSAID Vivlodex

David SalazarThe drug uses SoluMatrix’s Fine Particle Technology to meet FDA guidelines that an NSAID contain the smallest possible dose over the shortest amount of time to prevent adverse drug ...

Drugs and Medications [0 Results]

None

PubMed Articles [127 Associated PubMed Articles listed on BioPortfolio]

Removal of pharmaceuticals from secondary effluents by an electro-peroxone process.

This study compared the removal of pharmaceuticals from secondary effluents of wastewater treatment plants (WWTPs) by conventional ozonation and the electro-peroxone (E-peroxone) process, which involv...

Increased acute toxicity to fish caused by pharmaceuticals in hospital effluents in a pharmaceutical mixture and after solar irradiation.

Hospital effluents are an important source of residual drugs and other classes of pharmaceuticals in aquatic environments. The raw wastewater from the studied hospital exhibited acute toxicity to vert...

Ranking Prescribed Pharmaceuticals in Terms of Environmental Risk: Inclusion of Hospital Data and the Importance of Regular Review.

A newly available dataset on pharmaceuticals used in Scottish hospitals enabled an Environmental Risk Assessment that includes hospital consumption of pharmaceuticals, as previous UK rankings have bee...

Uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin and propranolol, in Daphnia magna.

The objective of the present study was to investigate the uptake, depuration, and bioconcentration of two pharmaceuticals, roxithromycin (ROX) and propranolol (PRP), in Daphnia magna via aqueous expos...

Acute toxicities of pharmaceuticals toward green algae. mode of action, biopharmaceutical drug disposition classification system and quantile regression models.

The acute toxicities of 36 pharmaceuticals towards green algae were estimated from a set of quantile regression models representing the first global quantitative structure-activity relationships. The ...

Clinical Trials [0 Results]

None

Companies [5 Associated Companies listed on BioPortfolio]

Iroko Pharmaceuticals, LLC

Iroko is a pharmaceutical company focused on specialty therapeutic areas. The company acquires, develops and maximizes the potential of currently marketed products on a global bas...

Iroko Pharmaceuticals, LLC and SynopiaRx LLC

Iroko is a pharmaceutical company focused on the development and commercialization of innovative specialty therapeutic products. The company acquires, develops and maximizes the p...

Iroko Cardio International Sàrl

IROKO Cardio has been founded to organize and support the commercial effort for Aggrastat. In close cooperation with our worldwide distribution partners, we aim to provide state o...

Iroko Pharmaceuticals Inc.

Iroko Pharmaceuticals, LLC and Aptuit Inc.

More Information about "Iroko Pharmaceuticals, LLC" on BioPortfolio

We have published hundreds of Iroko Pharmaceuticals, LLC news stories on BioPortfolio along with dozens of Iroko Pharmaceuticals, LLC Clinical Trials and PubMed Articles about Iroko Pharmaceuticals, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Iroko Pharmaceuticals, LLC Companies in our database. You can also find out about relevant Iroko Pharmaceuticals, LLC Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record